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Abstract: PET-CT is an exciting new imaging technology that
simultaneously acquires detailed structural and functional imaging
information. PET is having an increasing inpact on the management
of locoregionally advanced non-small cell lung cancer with radio-
therapy. PET combined with CT is much more accurate than CT
alone in staging lung cancer and patients treated with radical
radiotherapy or chemoradiotherapy have better outcomes because of
superior patient selection. PET also has the potential to improve
radiotherapy planning by minimizing unnecessary irradiation of
normal tissues and by reducing the risk of geographic
miss. PET influences treatment planning in a high proportion of
cases and therefore radiotherapy dose escalation without PET may
be futile.
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Metabolic imaging using 18F-fluorodeoxyglucose positronemission tomography (FDG-PET) is a major advance for
patients with loco-regionally advanced or medically unresect-
able non small cell lung cancer (NSCLC) who are candidates for
definitive or “radical” radiotherapy (RT). It provides a more
accurate estimate of the true extent of disease inside the thorax
compared to CT and is a sensitive method for detection of
distant metastasis outside the thorax. For radiotherapy to be
successful, all tumor must be included in the treatment volume
and the disease must not be too extensive to be safely treated to
a high radiation dose. Radical radiotherapy is generally offered
to patients with a good performance status and without weight
loss of more than 10% of body mass but is contraindicated in
those with malignant pleural effusion or uncontrolled distant
metastasis. Until recently, the results of radiotherapy in NSCLC
have been dismal, except for the subgroup of patients with
medically-inoperable stage I disease.1 A review of NSCLC
patients treated at the Peter MacCallum Cancer Centre in the
1980’s and early 1990’s, showed that only 6% of patients treated
with radical radiotherapy alone survived for 5 years.2 As a
consequence of such poor results, lung cancer patients with
unresectable tumors were often ignored by cancer researchers
and their treatment was given a low priority.3
Since the patients in that series were treated, two major
advances have occurred in management. The first is the
routine addition of platinum based chemotherapy to radio-
therapy. Randomized trials have shown that significant im-
provements in survival are obtained when chemotherapy is
added to high dose irradiation,4 especially when radio-sensi-
tizing platinum-based chemotherapy is given concurrently
with radiotherapy. The second major advance, pioneered by
our own group in Melbourne, is the routine use of FDG-PET
for patient selection and treatment planning.5 In our recently
updated series of patients with good performance status,
minimal weight loss, treated with predominantly chemo-
radiation and, most crucially, staged with PET, 5 year sur-
vival was 20%, (unpublised data). Of course, these results
are still not good enough but we believe that they can be
improved further with more effective loco-regional radiation
therapy combined with chemotherapy and perhaps in the
future with more effective biological agents. In this article the
complementary role of PET in patient selection and radio-
therapy planning will be discussed.
USE OF PET IN SELECTION OF PATIENTS FOR
RADICAL RADIOTHERAPY
Most radical RT candidates with NSCLC have stage
IIIA or stage IIIB disease. There is strong evidence that
FDG-PET can detect distant metastases and additional sites
of nodal involvement more frequently in patients already
known to have loco-regionally advanced disease on conven-
tional imaging, than in patients considered to have earlier
stage disease.6,7 PET therefore has the greatest influence on
treatment choice in patients already known to have locally
advanced disease. Our group reported an increase in the
incidence of PET detection of distant metastases with increas-
ing conventional (i.e. non-PET) stage from stage I (7.5%),
through stage II (18%) to stage III (24%, p0.016).7 In a
meta-analysis, primarily including earlier stage disease, un-
expected extra-thoracic metastases were detected with FDG-
PET in 12% of lung cancer patients and the therapeutic
management was changed in 18% of patients as a result of
PET findings.8 In our own series of 153 patients who were
candidates for radical RT before PET, 30% were found to be
unsuitable for aggressive therapy because of distant meta-
static or loco-regionally advanced disease and received pal-
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liative therapies instead.5 An immediate consequence of in-
corporation of PET into staging for patients planned for RT
for NSCLC is therefore an apparent improvement in survival
due to better patient selection. In a study from our own center,
survival for 2 similarly-treated cohorts of patients was com-
pared.9 The earlier cohort dated from the era immediately
before PET became available and the second cohort consisted
of PET staged patients. Median survival was almost twice as
long in the PET-staged group. PET detected metastases
should not be ignored as they are associated with relatively
short survival regardless of the treatment modality. Patients
treated with radical chemo-radiation have short survival if
PET scanning shows distant metastasis.
METASTASIS
All clinical trials of RT in advanced NSCLC that have
been carried out without the assistance of FDG-PET staging
have inevitably included large numbers of patients with gross
distant metastasis that would have been PET-detectable and
who would have been unable to benefit from aggressive local
therapies that they received. To make matters worse, it is
likely that the RT that was delivered to those patients fortu-
nate enough not to have gross metastatic disease often missed
or poorly-covered the target, most commonly because of
failure of computed tomography (CT)-based structural imag-
ing to appreciate the true status of the intrathoracic nodes.
Much of our knowledge of the efficacy of RT in lung cancer
is derived from studies in which RT was delivered to a target
volume determined using inadequate CT-based imaging. In
the next section the role of PET in planning radiotherapy will
be discussed.
USE OF PET IN RADIOTHERAPY PLANNING
FOR PATIENTS WITH NSCLC
When using treatment planning software to plan RT for
NSCLC, the first step is to use a pointing device, such as a
mouse, to draw around the margins, or “contour” the known
regions of gross tumor on CT slices of the thorax to define the
“gross tumor volume” or GTV. The planning target volume
(PTV) is an expansion of this contoured volume, allowing
margins for microscopic disease extension, variability in
treatment set-up and movement. A treatment plan is then
produced, using a number of conformally-shaped beams to
deliver radiation to the PTV as uniformly as possible, while
sparing normal tissues, especially lung, as much as possible.
In order to accurately deliver conformal RT for NSCLC, the
radiation oncologist must appreciate the true distribution of
gross disease in three-dimensional space. In addition there
must be an understanding of the effect of movement of the
tumor, most significantly with respiration and the cardiac
cycle.
Before PET became available, CT scanning represented
the most accurate imaging modality for planning RT in lung
cancer. It was a major advance over the use of plain X-rays
but CT has some well documented and serious limitations
when used to show the true extent of disease in patients with
NSCLC. Use of the conventional CT criterion of short axis
transverse diameter greater than 1cm to determine if there is
tumor in a mediastinal lymph node is notoriously inaccurate.
CT cannot detect tumor in normal-sized lymph nodes. The
Dwamena meta analysis clearly showed the superiority of
PET compared to CT for determining nodal status, especially
when PET information is combined with CT.10 CT cannot
usually delineate the boundary between atelectasis and tumor
clearly (Figure 1) and there is much guesswork involved in
contouring the target volume in such cases. Understandably,
there may be little consensus when different radiation oncolo-
gists are called upon to contour volumes in the same patients.
There is already evidence that the use of PET in
addition to CT can improve concordance between radiation
oncologists, especially in cases where there is atelectasis.11
The few prospective studies that have been published com-
paring target volumes produced with CT alone or PET plus
CT all show that PET significantly alters the target volume in
a high proportion of cases; for example more than 50% had
a significant change in the series reported by Bradley and
colleagues.12 This occurs most commonly because of differ-
FIGURE 1. Value of PET CT in defining gross tumor volume
(GTV) in atelectasis. In upper panel, collapse and consolida-
tion of right lower lobe is obvious on the CT scan but tumor
location cannot be identified. Tumor is readily apparent on
PET/CT image (lower panel) enabling radiotherapy planning
to proceed.
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ent assessments of nodal status by CT and PET. PET tends to
increase the number of nodes included in the target volume
although in some cases reactive enlarged nodes may be
excluded. In our own series we estimated that approximately
a quarter of patients would have had geographic miss without
PET.5
There are some technical issues to be considered when
using PET scans to define target volumes for RT. These
problems include a) the variability of FDG uptake within and
between tumors and normal tissues, b) the effects of inflam-
mation and infection, c) artifacts on scans such as apparent
leaching of signal from very FDG-avid structures into adja-
cent low avidity areas, d) partial volume effects in small
structures or at the edges of larger structures and e) the effects
of movement. CT scans are generally acquired instanta-
neously in a discrete part of the respiratory cycle whereas
PET information is an average of the uptake acquired over 30
minutes or so through many respirations (Figure 2). The PET
image is therefore blurred and expanded by the effect of
movement (unless acquisition is gated) but the CT image is
sharp. For non-gated treatment delivery, the larger blurred
PET volume is more appropriate for treatment planning.
However, for treatment planning, where is the edge of the
gross tumor on a PET-CT scan? Can a semi-automated
contouring approach using, for example, a standardized up-
take value (SUV) scale be employed?13 An alternative ap-
proach to the effect of movement is to use respiratory gating,
segmenting the CT and PET information into different phases
of respiration and planning and delivering therapy in the most
favorable phase of breathing (inspiration). Very promising
work on gating has been carried out in the Netherlands14 and
at Memorial Sloan Kettering Cancer Centre15 but these meth-
ods are too complex for routine use at present.
Unfortunately, there is no simple automated method for
contouring that can give reliable results given all of the
confounding factors in the far from exhaustive list given
above. It may be useful to know that a lesion has a high SUV
but it is not true that all regions of the thorax with an SUV
above (for example) 2.5 are tumor and that all areas with a
lower SUV are benign. The edge of a moving tumor may
have a low SUV and small FDG-avid nodes may have a low
measured SUV due to partial volume effects. Tumors often
have areas of necrosis within them that have low SUV. In any
case, the absolute level of measured SUV will vary according
to the technical details of the scan, including timing, blood
sugar level and type of scanner used.
What then should be done? Until better information is
available, perhaps from better technology or tracers, all of the
potentially confounding issues must be taken into account
when contouring the tumor in each individual case. A nuclear
medicine physician with adequate experience should be in-
volved in the process, as few radiation oncologists have
received specific training in this area. Relatively static tumor
lesions that have sharp CT contours and are FDG avid are
easy to contour. In more difficult situations, such as the
blurred edge of a moving tumor, the physician should take
account of all the clinical and imaging information, including
information about movement if available (e.g. fluoroscopy).
In such an instance, the decision to place the contour relies
upon the judgment of the radiation oncologist and the assis-
tance of the nuclear medicine physician. The best available
window settings should be used. A high level of concordance
can be achieved in most cases using such an approach.
Unfortunately, there can be no true “gold standard” or ideal
PTV in each patient because it is impossible to know with
certainty the exact tumor boundary in real time, either to
confirm or refute the PET-CT result. Therefore, as this
technology is introduced, physicians must be especially dil-
igent in their assessment of the results of treatment using
PET-CT planning.
THE FUTURE: DOSE ESCALATION USING
PET-DEFINED TARGET VOLUMES
Fewer than 20% of patients with NSCLC achieve
durable local control with conventional doses of chemo-
radiation and the great majority die from local progression,
distant metastases or both. Recent data from our own center
show that even in the most favorable patients, PET-staged
patients who attain a complete metabolic response (PET CR)
after radical chemo-radiation to 60Gy, loco-regional recur-
rence occurs in at least half of cases, often after several
years.16 Administration of higher radiation doses would al-
most certainly have improved local control rates in these
patients, however in the thorax normal tissues limit the dose
that can safely be given17 without excessive risks of fatal
pneumonitis or other lethal complications. New planning
tools and methods such as intensity modulated radiotherapy
offer the prospect of dose escalation to the tumor while
maintaining doses to normal tissues within acceptable limits.
It has been estimated that doses of 84Gy or more will be
required to control the majority of locally advanced lung
cancers.18 In the pre-PET era, it is likely that many patients
had tumors that were treated to much less than even the
FIGURE 2. Effect of respiratory motion on determination of
gross tumor volume (GTV) using PET/CT scanner. GTV de-
fined by PET (outlined in pink) was significantly more ante-
rior and medial than the GTV defined using a random CT
acquisition (outlined in yellow).
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inadequate prescribed dose because of geographic miss. It
would be naı¨ve to suppose that attainment of local control
with radiation could cure the majority of stage III patients but
there is already evidence from the CHART randomized trial
that more effective local therapy or a better local treatment
response will lead to a reduction in distant metastasis. Despite
the importance of systemic disease in NSCLC, it is an
unavoidable fact that no lung cancer patient can ever be cured
without loco-regional disease control. The available evidence
from published studies suggests that PET should be incorpo-
rated into future RT dose escalation studies in NSCLC. If any
benefit is to be obtained from dose escalation it will be most
easily seen in those patients who have all of their intra-
thoracic disease treated to a high dose and who do not have
distant metastases. Modeling by van Der Wel and colleagues
suggest that PET-based RT planning may significantly im-
prove the therapeutic ratio in lung cancer.19
CONCLUSIONS
The use of PET-CT to improve selection of patients and
for treatment planning in NSCLC is likely to significantly
improve the results of RT. PET-staged and planned patients
are much more likely to benefit from conformal dose escala-
tion approaches and it is possible that much of the published
literature on this topic is already obsolete!
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